###### Key questions

What is already known about this subject?
=========================================

-   Postoperative heart failure (PHF) that presents in the early course after cardiac surgery is the major cause of postoperative mortality after coronary artery bypass surgery.

-   In contrast, PHF after aortic valve replacement (AVR) for aortic stenosis (AS) usually is mild and transient with a low early mortality, but the serious consequences for long-term survival become apparent within a few years.

-   Methods to assess PHF are not well documented with regard to outcome.

-   N-terminal pro-B-type natriuretic peptide (NT-proBNP) is an established biomarker for heart failure and also a relevant marker for outcome in cardiac surgery.

What does this study add?
=========================

-   This study confirms that PHF after first-time AVR for AS is associated with a poor long-term survival, although it may initially appear benign.

-   The novel findings are that NT-proBNP level on the first postoperative day (POD1) provided good discrimination of PHF after AVR for AS and that the best cut-off level of NT-proBNP for PHF on POD1 (≥5290 ng/L) identified patients at particular risk of poor long-term survival.

How might this impact on clinical practice?
===========================================

-   NT-proBNP level on POD1 aids in the assessment of PHF and identifies patients at particular risk of poor long-term survival.

Introduction {#s1}
============

Postoperative heart failure (PHF) or low cardiac output syndrome typically presents at weaning from cardiopulmonary bypass (CPB) or during the first hours after surgery and is associated with a high early mortality after coronary artery bypass surgery (CABG).[@R1] Although PHF was associated with high postoperative mortality after aortic valve replacement (AVR) in a mixed high-risk cohort, our experience is that the serious consequences of PHF after AVR for aortic stenosis (AS) become evident only after a few years.[@R2] We found PHF to be an independent risk factor for poor long-term survival and speculated that an episode of PHF unmasks a myocardial factor, possibly associated with diastolic function, responsible for poor long-term outcome.[@R2] Although PHF usually is easily recognisable, methods to assess PHF with regard to outcome are not well documented. Therefore, markers that can be used for prediction and assessment of PHF would be desirable.

Natriuretic peptides, particularly N-terminal pro-B-type natriuretic peptide (NT-proBNP) and B-type natriuretic peptide (BNP), are established biomarkers for heart failure in cardiology practice.[@R4] In cardiac surgery, both preoperative and postoperative levels of NT-proBNP and BNP have been associated with adverse outcomes, treatment with inotropes and mechanical circulatory support.[@R6] In this prospective study, the NT-proBNP level was determined from the preoperative evaluation until 6 months after surgery in patients undergoing AVR for isolated AS. The primary aim was to investigate the association between NT-proBNP and PHF, and the secondary aim was to analyse the impact of PHF and NT-proBNP on long-term survival after AVR for AS.

Methods {#s2}
=======

Patients {#s2-1}
--------

The University Hospital in Linköping is a tertiary referral hospital and the only centre for cardiac surgery in the south-east region of Sweden, serving a population of approximately one million. All patients in the south-east region of Sweden undergoing preoperative evaluation for aortic valve surgery between June 2008 and January 2013 were screened for this prospective observational study.[@R12] The study population consisted of consecutive patients who provided written informed consent and were scheduled to undergo AVR for AS. Exclusion criteria were a lack of informed written consent, emergency procedures and active endocarditis. Patients were excluded if they underwent concomitant procedures, with the exception of a simultaneous supracoronary aortic graft that did not require circulatory arrest (n=26) or tricuspid valve procedure (n=5).

A total of 548 patients with aortic valve disease, eligible for an aortic valve intervention, were screened, and 462 patients were included in the original study at the preoperative evaluation. Patients with equally significant AS and aortic regurgitation (n=5) or patients undergoing surgery for aortic regurgitation (n=43), transcatheter aortic valve implantation (TAVI) (n=126), concomitant CABG (n=75), concomitant mitral valve surgery (n=5) or a concomitant maze procedure (n=5) were excluded. A flow chart of the patients is shown in [online supplementary figure 1](#SP1){ref-type="supplementary-material"}.
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Study design {#s2-2}
------------

This was a prospective, observational, longitudinal cohort study investigating (1) the discrimination of perioperative NT-proBNP for PHF according to prespecified criteria in patients undergoing AVR for AS and (2) the impact of PHF and NT-proBNP on long-term survival after AVR for AS. Venous blood samples for NT-proBNP were obtained at five time points: preoperative evaluation (PREEV), the day before the index procedure (PREOP), on the morning of the first (POD1) and third postoperative day (POD3), and at the 6-month follow-up. NT-proBNP was measured with an electrochemiluminescence immunoassay on a Roche Elecsys 2010 automated platform (Roche Diagnostics, Basel, Switzerland). The results were released from the laboratory when the trial was terminated. Further details about NT-proBNP analyses are given in the online supplementary methods.

Mixed venous oxygen saturation (SvO~2~) was measured at weaning from CPB, 5 min after administration of protamine, on admission to the intensive care unit (ICU), the next postoperative morning and whenever warranted by the haemodynamic state. Arterial blood pressure, central venous pressure and pulmonary artery pressure were monitored continuously. Transoesophageal echocardiography was routinely used. Demographic and perioperative data were registered prospectively in a computerised institutional database (Carath V.5.4, Fujitsu). All fields were defined in a data dictionary. Mortality data were retrieved from the Swedish Civil Registry.

Study endpoints {#s2-3}
---------------

The primary endpoint was PHF. The secondary endpoint was all-cause mortality during follow-up.

Definitions {#s2-4}
-----------

The definition of PHF was a haemodynamic state when the cardiac output does not meet the systemic demand, despite correction of volume or vascular resistance. Mixed SvO~2~ in relation to systolic arterial blood pressure (SAP), not explained by anaemia, hypovolaemia or shivering, was used to define this haemodynamic state[@R13]: SvO~2~ \<50% and SAP \<130 mm Hg; SvO~2~ \<55% and SAP \<110 mm Hg; SvO~2~ \<60% and SAP \<90 mm Hg. Severe PHF was defined as PHF leading to death or an extended ICU stay (≥72 hours) in patients requiring treatment with an intra-aortic balloon pump or at least one inotropic agent with the following dosages ≥24 hours after admission to the ICU: epinephrine ≥0.033 µg/kg/min, milrinone ≥0.375 µg/kg/min, dopamine ≥4 µg/kg/min, dobutamine ≥4 µg/kg/min or levosimendan regardless of dose.

Definitions for acute kidney injury, postoperative stroke, postoperative myocardial infarction, patient prosthesis mismatch, moderate and severe left ventricular (LV) dysfunction, and diabetes mellitus are given in the online supplementary methods.

Statistical analysis {#s2-5}
--------------------

Categorical variables are presented as percentage (number). Continuous variables that were not normally distributed are expressed as median with IQR. Categorical data were compared with Fisher's exact test. For continuous variables not following a normal distribution, the Mann-Whitney U test and Wilcoxon signed-rank test were used, as appropriate. A receiver operating characteristic analysis was carried out to calculate the area under the curve (AUC) to evaluate the discrimination of NT-proBNP for PHF. Youden's Index was used for calculation of the best cut-off point with regard to sensitivity and specificity.

Risk factors and predictors for PHF were identified with backward conditional stepwise multivariable logistic regression. Hosmer-Lemeshow goodness-of-fit statistics were calculated for the final model. Clinically relevant variables for heart failure, known extracardiac confounders for NT-proBNP and all variables with a p value \<0.25 in the univariable analysis were tested in the multivariable model ([online supplementary tables 1 and 2](#SP1){ref-type="supplementary-material"}).

Survival curves were generated by means of Kaplan-Meier estimates, and differences in survival were compared with the log-rank test. Cox proportional hazards regression models were used to identify risk factors for mortality during follow-up. To avoid data loss, missing data were managed with pairwise deletion when possible. Analyses of sequential data over time were checked with analyses using listwise deletion to exclude conflicting results. A p value \<0.05 was considered statistically significant; all p values were two-sided. Statistical analyses were performed with SPSS Statistics V.23 for Windows and Statistica V.12.0 (StatSoft, Tulsa, Oklahoma).

Results {#s3}
=======

There were a total of 203 consenting patients with AS undergoing first-time AVR with at least one available NT-proBNP level at the following time points: PREEV (n=195), PREOP (n=199), POD1 (n=192), POD3 (n=186) and 6-month follow-up (n=181). The overall 30-day mortality was 0.5%. The preoperative, intraoperative and postoperative characteristics of all patients and those with and without PHF are presented in [tables 1 and 2](#T1 T2){ref-type="table"}. Preoperatively, patients with PHF had a significantly higher proportion of moderate or severe LV dysfunction, congestive heart failure, renal dysfunction, pulmonary hypertension and higher European System for Cardiac Operative Risk Evaluation II score. Intraoperatively, they had longer CPB times and aortic cross-clamp times.

###### 

Preoperative and intraoperative characteristics of all patients and those with or without PHF

  -----------------------------------------------------------------------------------------------------------
                                      All patients\       With PHF\           Without PHF\        P value\*
                                      (N=203)             (n=18)              (n=185)             
  ----------------------------------- ------------------- ------------------- ------------------- -----------
  Age (years)                         70 (65--77)         73 (69--78)         70 (64--76)         0.23

  Female gender                       50 (102)            39 (7)              51 (95)             0.34

  NT-proBNP PREEV (ng/L)              390 (180--995)      825 (215--3030)     380 (180--905)      0.08

  NT-proBNP PREOP (ng/L)              460 (180--1120)     960 (170--3810)     430 (180--1030)     0.14

  BMI (kg/m^2^)                       27 (24--30)         26 (24--31)         27 (24--30)         0.68

  Obesity (BMI ≥30 kg/m^2^)           28 (56)             28 (5)              28 (51)             1

  BSA (m^2^)                          1.88 (1.75--2.05)   1.91 (1.83--2.02)   1.88 (1.74--2.06)   0.61

  Haemoglobin (g/L)                   139 (129--147)      132 (113--143)      139 (130--148)      0.048

  p-Creatinine (µmol/L)               84 (71--99)         100 (81--113)       82 (70--98)         0.007

  eGFR (mL/min/1.73 m^2^)             68 (58--82)         61 (48--71)         68 (59--82)         0.015

  p-Albumin (g/L)                     41 (38--43)         42 (37--43)         41 (38--43)         0.60

  p-Cystatin C (mg/L)                 1.15 (0.99--1.31)   1.38 (1.14--1.88)   1.14 (1.00--1.30)   0.004

  Diabetes                            15 (30)             11 (2)              15 (28)             1

  Hypertension                        53 (107)            44 (8)              54 (99)             0.47

  COPD                                4 (9)               6 (1)               4 (8)               0.57

  Dyspnoea                            75 (152)            89 (16)             74 (136)            0.25

  Angina                              29 (59)             39 (7)              28 (52)             0.42

  Syncope                             11 (23)             6% (1)              12 (22)             0.7

  Echocardiographic indication        15 (31)             5 (1)               16 (30)             0.32

  NYHA III--IV                        54 (110)            78 (14)             52 (96)             0.047

  NYHA IV                             1 (2)               6 (1)               0.5 (1)             0.17

  CHF                                 11 (23)             33 (6)              9 (17)              0.009

  AMI \<90 days                       0.5% (1)            0                   0.5 (1)             1

  Moderate or severe LV dysfunction   9 (18)              28 (5)              7 (13)              0.013

  Severe LV dysfunction               2 (5)               6 (1)               2 (4)               0.37

  Pulmonary hypertension              6 (13)              28 (5)              4 (8)               0.003

  Additive EuroSCORE                  6 (4--7)            7 (5--9)            6 (4--7)            0.042

  EuroSCORE II                        1.6 (1.1--2.8)      2.1 (1.9--5.6)      1.5 (1.1--2.7)      0.002

  CPB time (min)                      91 (79--106)        106 (96--160)       89 (79--104)        0.001

  Aortic cross-clamp time (min)       66 (58--78)         77 (65--92)         65 (57--77)         0.017
  -----------------------------------------------------------------------------------------------------------

Data given as median (IQR) or percentage (n).

\*PHF versus without PHF.

AMI, acute myocardial infarction;BMI, body mass index;BSA, body surface area;CHF, congestive heart failure;COPD, chronic obstructive pulmonary disease;CPB, cardiopulmonary bypass;EuroSCORE, European System for Cardiac Operative Risk Evaluation;LV, left ventricular;MDRD formula, Modification of Diet in Renal Disease formula; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association functional classification;PHF, postoperative heart failure; PREEV, preoperative evaluation;PREOP, the day before index procedure; eGFR, estimated glomerular filtration rate according to MDRD formula;p, plasma.

###### 

Postoperative characteristics of all patients and those with or without PHF

  ------------------------------------------------------------------------------------------------------------
                                       All patients\       With PHF\           Without PHF\        P value\*
                                       (N=203)             (n=18)              (n=185)             
  ------------------------------------ ------------------- ------------------- ------------------- -----------
  NT-proBNP POD1 (ng/L)                2595 (1590--4065)   6415\               2445\               \<0.0001
                                                           (3145--11220)       (1540--3855)        

  ∆NT-proBNP POD1--PREOP (ng/L)        1756 (1080--2750)   3000\               1726\               0.023
                                                           (1580--6295)        (1020--2590)        

  NT-proBNP POD3 (ng/L)                3920 (2590--6690)   5530\               3840\               0.08
                                                           (3370--8460)        (2540--6210)        

  ∆NT-proBNP POD3--PREOP (ng/L)        3020 (1871--4760)   2850\               3040\               0.58
                                                           (925--4320)         (1891--4760)        

  6-month follow-up NT-proBNP (ng/L)   310 (170--730)      340\                300\                0.08
                                                           (260--2310)         (165--665)          

  PPM                                  79 (143/181)        92 (11/12)          78 (132/169)        0.47

  Severe PPM                           38 (69/181)         42 (5/12)           38 (64/169)         0.77

  ICU stay (hours)                     21 (17--23)         21 (21--135)        21 (17--22)         \<0.0001

  ICU stay \>72 hours                  4 (8)               33 (6)              1 (2)               \<0.0001

  Ventilation time (hours)             3 (2--5)            8 (3--25)           3 (2--5)            \<0.0001

  Ventilation time \>48 hours          2 (4)               17 (3)              0.5 (1)             0.002

  Postoperative stroke                 1 (2)               --                  1 (2)               1

  p-Troponin T POD3 (ng/L)             290 (201--467)      725 (414--838)      272 (189--430)      \<0.0001

  p-CK-MB POD1 (μg/L)                  18 (13--25)         30 (19--58)         17 (13--24)         0.002

  p-CK-MB POD1 \>50 µg/L               4 (8)               28 (5)              2 (3)               \<0.0001

  PMI                                  2 (4)               17 (3)              0.5 (1)             0.002

  p-Cystatin C POD3 (mg/L)             1.34 (1.13--1.64)   1.96 (1.41--2.36)   1.32 (1.11--1.56)   \<0.0001

  Acute kidney injury                  10 (20)             22 (4)              9 (16)              0.09

  30-day mortality                     0.5 (1)             0                   0.5 (1)             1
  ------------------------------------------------------------------------------------------------------------

Data given as median (IQR) or percentage (n).

\*PHF versus without PHF.

CK-MB, creatine kinase-MB isoenzyme;ICU, intensive care unit;NT-proBNP, N-terminal pro-B-type natriuretic peptide; p, plasma;PHF, postoperative heart failure;PMI, postoperative myocardial infarction;POD1, first postoperative day;POD3, third postoperative day;PPM, patient prosthesis mismatch; PREOP, the day before the index procedure.

Of the 18 patients who fulfilled the study criteria for PHF, 2 had mild transient PHF that resolved without inotropes. Three patients developed severe PHF. No patient with PHF died within 30 days after surgery, but PHF was associated with a significantly longer ICU stay and ventilation time, more signs of myocardial injury, and renal dysfunction ([table 2](#T2){ref-type="table"}). Overall 30 patients (15%) were treated with inotropes at some stage intraoperatively or postoperatively. Patients classified as having PHF had a significantly longer ICU stay and more signs of myocardial and renal injury than those treated with inotropes who did not fulfil the study criteria for PHF ([online supplementary table 3](#SP1){ref-type="supplementary-material"}).

Perioperative NT-proBNP levels in relation to PHF {#s3-1}
-------------------------------------------------

The NT-proBNP level increased postoperatively in all patients, but this was significantly more pronounced on POD1 in patients with PHF versus those without PHF (6415 (3145--11220) vs 2445 (1540--3855) ng/L, p\<0.0001) ([table 2](#T2){ref-type="table"}, [figure 1](#F1){ref-type="fig"}). The average peak level was recorded on POD1 in the PHF cohort and on POD3 in the cohort without PHF. The NT-proBNP level on POD1 demonstrated good discrimination for PHF (AUC 0.82, 95% CI 0.72 to 0.91, p\<0.0001). The best cut-off value of 5290 ng/L[@R1] had a sensitivity of 63% and a specificity of 85% ([figure 2](#F2){ref-type="fig"}). Poor discrimination was found preoperatively and later in the postoperative course ([figure 2](#F2){ref-type="fig"}).

![NT-proBNP levels (ng/L) before and after surgery in patients with PHF (black bars) and without PHF (white bars). Data are expressed as median with IQR; \*p\<0.05. 6 months postop, 6-month follow-up; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PHF, postoperative heart failure; POD1, first postoperative day; POD3, third postoperative day; PREEV, preoperative evaluation; PREOP, the day before the index procedure.](openhrt-2019-001063f01){#F1}

![Discrimination of perioperative NT-proBNP for postoperative heart failure (PHF) in patients undergoing aortic valve replacement (AVR) for aortic stenosis (AS). According to receiver operating characteristic analyses, the NT-proBNP level on the first postoperative day (POD1) demonstrated good discrimination for PHF in patients undergoing AVR for AS (area under the curve (AUC)=0.82, 95% CI 0.72 to 0.91, p\<0.0001; best cut-off 5290 ng/L with a sensitivity of 63% and a specificity of 85%), whereas the discrimination of NT-proBNP for PHF was less convincing on the day before the index procedure (PREOP) and on the third postoperative day (POD3) (PREOP: AUC=0.61, 95% CI 0.44 to 0.78, p=0.14; POD3: AUC=0.63, 95% CI 0.49 to 0.77, p=0.08). NT-proBNP, N-terminal pro-B-type natriuretic peptide.](openhrt-2019-001063f02){#F2}

NT-proBNP POD1 level ≥5290 ng/L and plasma creatine kinase-MB isoenzyme POD1 \>50 µg/L emerged as significant predictors of PHF according to multivariable logistic regression ([online supplementary table 1](#SP1){ref-type="supplementary-material"}). Variables associated with PHF according to univariate analysis are given in [online supplementary table 2](#SP1){ref-type="supplementary-material"}.

Patients with an NT-proBNP level ≥5290 ng/L on POD1 had a significantly longer ICU stay and more signs of myocardial and renal injury. None of these patients died within 30 days ([online supplementary table 4](#SP1){ref-type="supplementary-material"}).

Long-term survival related to PHF and NT-proBNP {#s3-2}
-----------------------------------------------

The mean follow-up from the entry into the study was 8.6±1.1 years (range 6.5--10.5 years). During this period, there were 48 deaths. Cumulative survival was significantly impaired in patients with PHF and an NT-proBNP level ≥5290 ng/L on POD1 ([figures 3 and 4](#F3 F4){ref-type="fig"}). The cumulative survival in patients with PHF was impaired if the NT-proBNP level was ≥5290 ng/L on POD1 ([figure 5](#F5){ref-type="fig"}). The unadjusted HR for PHF for long-term mortality was 3.01 (95% CI 1.45 to 6.21, p=0.003). The unadjusted HR for patients with an NT-proBNP level ≥5290 ng/L on POD1 for long-term mortality was 3.25 (95% CI 1.77 to 5.97, p\<0.0001).

![Cumulative survival (Kaplan-Meier) for patients with (dashed line) or without (solid line) postoperative heart failure (PHF).](openhrt-2019-001063f03){#F3}

![Cumulative survival (Kaplan-Meier) for patients with an NT-proBNP level ≥5290 ng/L (dashed line) or \<5290 ng/L (solid line) on POD1. NT-proBNP, N-terminal pro-B-type natriuretic peptide; POD1, first postoperative day.](openhrt-2019-001063f04){#F4}

![Cumulative survival (Kaplan-Meier) in the subgroup with PHF for patients with an NT-proBNP level ≥5290 ng/L (dashed line) or \<5290 ng/L (solid line) on POD1. The NT-proBNP level on POD1 was missing in two patients (one died 6 years after surgery, the other one was alive 7 years after surgery). NT-proBNP, N-terminal pro-B-type natriuretic peptide; PHF, postoperative heart failure; POD1, first postoperative day.](openhrt-2019-001063f05){#F5}

The unadjusted HR for patients having both PHF and an NT-proBNP level ≥5290 ng/L on POD1 for long-term mortality was 7.72 (95% CI 3.53 to 16.9, p\<0.0001). In the multivariable Cox regression model, PHF with an NT-proBNP level ≥5290 ng/L on POD1 emerged as a predictor of long-term mortality (HR 6.20, 95% CI 2.72 to 14.12, p\<0.0001), together with preoperative NT-proBNP, age and diabetes mellitus ([table 3](#T3){ref-type="table"}). The univariate HRs for other variables tested in the multivariable Cox regression are shown in [online supplementary table 5](#SP1){ref-type="supplementary-material"}.

###### 

HR for long-term mortality in the multivariable regression model

  Variable                             HR (95% CI)           P value
  ------------------------------------ --------------------- ----------
  PHF with NT-proBNP POD1 ≥5290 ng/L   6.20 (2.72 to 14.1)   \<0.0001
  NT-proBNP PREOP ≥825 ng/L            2.80 (1.48 to 5.29)   0.002
  Age (years)                          1.07 (1.02 to 1.11)   0.002
  Diabetes mellitus                    2.42 (1.22 to 4.80)   0.011

NT-proBNP, N-terminal pro-B-type natriuretic peptide; PHF, postoperative heart failure; POD1, first postoperative day;PREOP, the day before index procedure.

Discussion {#s4}
==========

This prospective study confirms previous findings that PHF after first-time AVR for AS is associated with a poor long-term prognosis after an apparently benign initial course. The novel findings are that the NT-proBNP level on POD1 provided good discrimination of PHF in this cohort and that the best cut-off NT-proBNP level on POD1 (≥5290 ng/L) identified patients at particular risk of poor long-term survival.

We have previously reported that postoperative mortality associated with PHF after AVR for AS is low compared with PHF after CABG and the serious consequences of PHF only become evident with time.[@R2] In this study, none of the patients with PHF died early after surgery, but late mortality was high, in agreement with our previous study.[@R2] In the early postoperative phase, PHF was associated with a longer ICU stay and ventilation time, more signs of myocardial injury, and renal dysfunction. Maganti *et al* reported a high early mortality associated with low cardiac output syndrome after AVR, but their study included all aortic valve procedures with a high proportion of emergency procedures, reoperations and endocarditis, with preoperative renal dysfunction and shock emerging as important risk factors.[@R3] In our previous retrospective study, an unselected population of patients from south-eastern Sweden undergoing AVR for AS for the first time were studied, and this prospective cohort only differed by including elective patients.[@R2]

A history of congestive heart failure, hypertension, pulmonary hypertension, severe systolic LV dysfunction, preoperative haemodynamic instability, intraoperative myocardial infarction and an extended aortic cross-clamping time were identified as risk factors for PHF after AS in our previous study.[@R16] The current study did not include emergency patients, but in general the results support these findings, as patients with PHF had a significantly higher proportion of moderate or severe LV dysfunction, preoperative congestive heart failure, pulmonary hypertension, postoperative myocardial infarction, and longer aortic cross-clamping time.

In cardiac surgery, both high preoperative and postoperative levels of natriuretic peptides have been associated with major cardiac events, treatment with inotropes, an extended ICU stay, ventricular dysfunction and mortality.[@R6] Similarly, the present study found patients with an NT-proBNP level on POD1 above the cut-off had significantly longer ICU stays, more signs of myocardial injury, higher incidences of renal injury and impaired long-term survival. In this study, only the NT-proBNP level on POD1 provided good discrimination for PHF. The reasons for the inconclusive results preoperatively and later in the postoperative course are unclear, and the results should be interpreted cautiously given the low number of events. However, in a recent study, the preoperative NT-proBNP level predicted PHF in patients undergoing CABG or surgery for mitral valve regurgitation, whereas the predictive value was less convincing in patients undergoing surgery for AS.[@R19] A possible reason is that a substantial proportion of PHF after AVR for AS occurs unexpectedly due to intraoperatively acquired myocardial dysfunction in low-risk patients.[@R16]

In our previous retrospective study, PHF emerged as an independent risk factor for long-term mortality after AVR for AS together with older age, preoperative renal dysfunction, procedure-associated stroke, body mass index \<19 kg/m^2^, preoperative atrial fibrillation and preoperative anaemia.[@R2] This prospective study confirms the negative impact of PHF, older age and renal dysfunction on long-term survival after AVR for AS, and also suggests a role for diabetes mellitus. When we first reported the delayed serious consequences of PHF after AVR for AS, we speculated that an episode of PHF unmasks a myocardial factor responsible for the poor long-term outcome. The finding that NT-proBNP can identify which patients with PHF are at risk of poor long-term survival supports this assumption. As the previous and current study adjusted for systolic LV function, the myocardial factor may be related to myocardial fibrosis and diastolic function.[@R2] The preoperative NT-proBNP level also emerged as a risk factor for long-term mortality, adding further support to the theory about an underlying myocardial factor, but the role of diastolic function for long-term survival after AVR for AS remains controversial and requires further investigation.[@R20]

Natriuretic peptides can provide important additional information to clinical and echocardiographic evaluations.[@R11] The role of natriuretic peptides in the early postoperative course after AVR for AS is supported by Nozohoor *et al*, who found that high BNP level on arrival to the ICU was an independent predictor of PHF after AVR.[@R17] In our study the average peak level of NT-proBNP was recorded on POD1 in patients with PHF compared with POD3 in those without PHF. Thus, it seems plausible that natriuretic peptides, early after AVR for AS, best reflect the preoperative condition of the heart and myocardial dysfunction sustained during surgery. The current results show that an NT-proBNP level ≥5290 ng/L on POD1 can help identify which patients with PHF after AVR for AS are at risk of poor long-term survival and require increased postoperative surveillance. This is important because the delayed consequences of PHF after AVR for AS may be almost equally profound in patients who were considered low-risk preoperatively.[@R21]

Study limitations {#s4-1}
-----------------

This study has limitations. The criteria used for the diagnosis of PHF in our study are inevitably questionable due to the lack of universally accepted criteria. PHF can be seen as a haemodynamic state when the cardiac output does not meet the systemic demand without supportive measures other than correction of volume or vascular resistance. However, cardiac output can be low even in patients with a completely normal postoperative course due to low systemic demands in anaesthetised patients early after cardiac surgery.[@R22] We defined PHF by use of mixed SvO~2~, which reflects the balance between oxygen delivery and systemic oxygen demand, and is well documented with regard to outcome after cardiac surgery.[@R13] Furthermore, well-known pitfalls such as shivering, anaemia and hypovolaemia were taken into account by the clinical endpoints committee.[@R22] The outcome in patients with PHF, compared with those treated with inotropes who did not fulfil the criteria for PHF, suggests that the criteria used by the blinded endpoints committee identified the sickest patients ([online supplementary table 3](#SP1){ref-type="supplementary-material"}). Although this is one of the largest prospective cohort studies on PHF in surgical AVR patients, the major limitation is the low number of events. Some data, such as perioperative atrial fibrillation, that could influence postoperative NT-proBNP and long-term survival were not available. The strengths of this study are that it was a prospective observational study screening all patients undergoing evaluation for aortic valve disease over almost 5 years in the south-eastern region of Sweden. Furthermore, a homogeneous cohort of patients undergoing AVR for AS were studied, and patients having TAVI or surgery for aortic regurgitation were excluded due to different levels of natriuretic peptides both preoperatively and postoperatively.[@R12]

Conclusion {#s5}
==========

This study confirms that PHF after first-time AVR for AS is associated with a poor long-term prognosis, although it may initially appear benign. The NT-proBNP level obtained on POD1 provided good discrimination of PHF in this cohort, and an NT-proBNP level ≥5290 ng/L on POD1 identified which patients with PHF had an increased risk of poor long-term survival.
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